Prognostic significance of fusion partners and KRAS mutations according to risk subgroup based on fusion patterns in MLL-r AML. (A) Comparison of EFS and OS in patients, according to MLL fusion partners. (B) Frequency of KRAS mutations in the high-risk group (MLLT10+MLLT4+MLLT1; n = 60) and intermediate-to-low–risk group (MLLT3+ELL+others; n = 100). (C-D) Prognostic significance of KRAS mutations in pediatric patients with MLL-r AML with high-risk fusion partners (MLLT10+MLLT4+MLLT1; n = 60) (C) and with intermediate-to-low–risk fusion partners (MLLT3+ELL+others; n = 100) (D).